Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PLGF


Brief Information

Name:Placental Growth Factor
Target Synonym:PGFL,Placental Growth Factor-Like,SHGC-10760,D12S1900,PlGF-2,PIGF,Placenta growth factor,PlGF,PGF,Placental Growth Factor,Placental Growth Factor, Vascular Endothelial Growth Factor-Related Protein
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

Human PLGF (19-149), Fc TagHuman PLGF (19-149), Fc Tag (Cat. No. PGF-H5256) ELISA bioactivity

Immobilized Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) at 2 μg/mL (100 μL/well) can bind Human PLGF (19-149), Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.1-3 ng/mL (QC tested).

PLGF MALS images

The purity of Human PLGF (19-221), Fc Tag (Cat. No. PGF-H5255) is more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.

Synonym Name



Placental growth factor (PGF) is also known as vascular endothelial growth factor-related protein, PLGF and PlGF2, is a member of the VEGF (vascular endothelial growth factor) sub-family - a key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. The main source of PGF during pregnancy is the placental trophoblast. PGF is also expressed in many other tissues, including the villous trophoblast. PGF is actived in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. PlGF2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ziv-aflibercept BAY-865321; AVE-0005 Approved Regeneron Pharmaceuticals Inc, Sanofi Zaltrap United States Colorectal Neoplasms Sanofi 2012-08-03 Lymphoma; Urethral Neoplasms; Breast Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Carcinoma, Mucoepidermoid; Genital Neoplasms, Female; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Ureteral Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Uterine Neoplasms; Endometrial Neoplasms; Glioma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Leiomyosarcoma; Solid tumours; Multiple Endocrine Neoplasia Type 1; Leukemia; Rectal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Ovarian Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Papillary; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Ascites; Lung Diseases; Adenoc Details
Aflibercept BAT-86-5321; BAY-865321 Approved Regeneron Pharmaceuticals Inc, Bayer AG Eylea, 艾力雅 United States Macular Degeneration; Macular Edema Regeneron Pharmaceuticals Inc 2011-11-18 Diabetic macular oedema; Choroidal Neovascularization; Diabetic Retinopathy; Corneal Neovascularization; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Retinopathy of Prematurity; Retinal Vein Occlusion; Neoplasm Metastasis; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Vitreous Hemorrhage; Diabetes Complications; Colorectal Neoplasms; Retinitis Pigmentosa; Diabetes Mellitus, Type 1; Prostatic Neoplasms; Wet Macular Degeneration; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Central Serous Chorioretinopathy; Colonic Neoplasms; Neoplasms; Rectal Neoplasms; Choroid Diseases; Glaucoma, Neovascular; Macular Edema; Diabetes Mellitus, Type 2; Cataract Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Aflibercept Biosimilar(Alvotech Swiss) AVT-06 Phase 3 Clinical Alvotech Swiss Ag Macular Degeneration Details
Aflibercept biosimilar (Mabwell) 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 Phase 3 Clinical Mabwell (Shanghai) Bioscience Co Ltd Diabetic macular oedema Details
Aflibercept biosimilar (Sam Chun Dang Pharm) SCD-411 Phase 3 Clinical Sam Chun Dang Pharm Co Ltd Macular Degeneration Details
Aflibercept biosimilar (Momenta/Mylan) M-710; MYL-1701P Phase 3 Clinical Mylan Nv, Momenta Diabetic macular oedema Details
Aflibercept biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Macular Degeneration Details
Aflibercept biosimilar (Zein Bioteccnology) Phase 1 Clinical Zein Bioteccnology Co Ltd Diabetic macular oedema Details
Ziv-aflibercept biosimiliar (Boan Biopharma) LY-01012; BA-1103 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Colorectal Neoplasms Details
CT-P42 CT-P42 Phase 3 Clinical Celltrion Inc Diabetic macular oedema Details
4D-150 4D-150 Phase 2 Clinical 4d Molecular Therapeutics Inc Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy Details
Anti-placental growth factor monoclonal antibody αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 Phase 2 Clinical Thrombogenics, Bioinvent International Ab Solid tumours; Retinal Telangiectasis; Ovarian Neoplasms; Medulloblastoma; Macular Edema; Glioblastoma; Colorectal Neoplasms; Diabetic Retinopathy; Carcinoma, Hepatocellular; Diabetes Mellitus; Macular Degeneration Details
Aflibercept biosimilar (HEXAL/Sandoz) SOK-583A1; SOK583A1; SOK-583 Phase 3 Clinical Sandoz, Hexal Macular Degeneration Details
Aflibercept Biosimilar (Boan Biopharma/Luye Pharma) LY-09004; BA-9101; OT-702 Phase 3 Clinical Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd Wet Macular Degeneration; Macular Degeneration Details
Aflibercept biosimilar (Samsung Bioepis) SB-15 Phase 3 Clinical Samsung Bioepis Co Ltd Macular Degeneration Details
FYB-203 FYB-203 Phase 3 Clinical Formycon Macular Degeneration Details
Aflibercept biosimilar (Amgen) ABP-938 Phase 3 Clinical Amgen Inc Vascular Diseases; Macular Degeneration Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message